Results 161 to 170 of about 57,585 (206)

Building the Tools for Enhanced Waterway Surveillance: Prediction of Antimicrobial‐Resistant Escherichia coli and Their Genes From an Urban River in Aotearoa New Zealand

open access: yesJournal of the Royal Society of New Zealand, Volume 56, Issue 4, August 2026.
Urban waterways are important reservoirs and transmission pathways for antimicrobial resistance (AMR), but AMR measurements are not routine in water quality monitoring. This two‐year environmental study investigated the prevalence, diversity and surveillance potential of AMR Escherichia coli in the Ōtākaro/Avon River and tributaries in Ōtautahi ...
Sophie van Hamelsveld   +8 more
wiley   +1 more source

Empagliflozin Versus Dapagliflozin and Urogenital Adverse Events in Type 2 Diabetes: A Target Trial Emulation

open access: yesDiabetes, Obesity and Metabolism, Volume 28, Issue 8, Page 7367-7379, August 2026.
ABSTRACT Aims Urogenital adverse events are common with sodium‐glucose co‐transporter 2 inhibitors (SGLT2i) and may influence treatment decisions. Variations in SGLT2i selectivity, potency and effects on renal glucose excretion could lead to differences in safety profiles. We compared the risks of urinary tract infection (UTI), genital tract infection (
Christine Ljungberg   +7 more
wiley   +1 more source

Standardization of postoperative adverse event reporting: A critical opportunity for improvement within the National Clinical Trials Network

open access: yes
Cancer, Volume 132, Issue 15, 1 August 2026.
Beth Helmink   +9 more
wiley   +1 more source

Risk of urinary tract infection with SGLT2 inhibitor initiation in patients with immune‐mediated inflammatory diseases and type 2 diabetes: A target trial emulation using a Japanese hospital‐based claims database

open access: yesJournal of Diabetes Investigation, Volume 17, Issue 8, Page 1310-1321, August 2026.
In this target trial emulation of patients with immune‐mediated inflammatory diseases and type 2 diabetes, SGLT2 inhibitor initiation was not associated with a clear increase in UTI risk versus metformin, including across immunosuppressive therapy strata.
Hiroshi Tsushima   +6 more
wiley   +1 more source

Risk Factors for Recurrent Urinary Tract Infections in Female Patients: A Systematic Review of Behavioral and Gynecologic Determinants. [PDF]

open access: yesCureus
Alhazmi SM   +14 more
europepmc   +1 more source

Discontinuation of SGLT2i After a Urogenital Infection: A Population-Based Matched Cohort Study of Patients With Type 2 Diabetes. [PDF]

open access: yesDiabetes Obes Metab
Ljungberg C   +5 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy